KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash from Financing Activities (2016 - 2026)

Emergent BioSolutions has reported Cash from Financing Activities over the past 17 years, most recently at -$11.4 million for Q1 2026.

  • For Q1 2026, Cash from Financing Activities fell 2750.0% year-over-year to -$11.4 million; the TTM value through Mar 2026 reached -$147.6 million, up 36.13%, while the annual FY2025 figure was -$136.6 million, 28.11% up from the prior year.
  • Cash from Financing Activities for Q1 2026 was -$11.4 million at Emergent BioSolutions, up from -$113.9 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $353.1 million in Q4 2022 and troughed at -$486.9 million in Q2 2023.
  • A 5-year average of -$23.1 million and a median of -$11.4 million in 2026 define the central range for Cash from Financing Activities.
  • Biggest five-year swings in Cash from Financing Activities: surged 4686.0% in 2022 and later tumbled 22880.0% in 2025.
  • Year by year, Cash from Financing Activities stood at $353.1 million in 2022, then tumbled by 98.67% to $4.7 million in 2023, then plummeted by 89.36% to $500000.0 in 2024, then tumbled by 22880.0% to -$113.9 million in 2025, then soared by 89.99% to -$11.4 million in 2026.
  • Business Quant data shows Cash from Financing Activities for EBS at -$11.4 million in Q1 2026, -$113.9 million in Q4 2025, and -$15.9 million in Q3 2025.